- Home
- BOOT vs BHVN Comparison
BOOT vs BHVN Comparison
Compare BOOT & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOOT
- BHVN
- Stock Information
- Founded
- BOOT 1978
- BHVN 2013
- Country
- BOOT United States
- BHVN United States
- Employees
- BOOT N/A
- BHVN N/A
- Industry
- BOOT Clothing/Shoe/Accessory Stores
- BHVN Biotechnology: Pharmaceutical Preparations
- Sector
- BOOT Consumer Discretionary
- BHVN Health Care
- Exchange
- BOOT Nasdaq
- BHVN Nasdaq
- Market Cap
- BOOT 3.3B
- BHVN 2.9B
- IPO Year
- BOOT 2014
- BHVN 2017
- Fundamental
- Price
- BOOT $104.08
- BHVN $27.65
- Analyst Decision
- BOOT Strong Buy
- BHVN Strong Buy
- Analyst Count
- BOOT 12
- BHVN 14
- Target Price
- BOOT $180.42
- BHVN $63.15
- AVG Volume (30 Days)
- BOOT 891.6K
- BHVN 1.2M
- Earning Date
- BOOT 05-13-2025
- BHVN 03-03-2025
- Dividend Yield
- BOOT N/A
- BHVN N/A
- EPS Growth
- BOOT 4.37
- BHVN N/A
- EPS
- BOOT 5.60
- BHVN N/A
- Revenue
- BOOT $1,845,814,000.00
- BHVN N/A
- Revenue This Year
- BOOT $17.28
- BHVN N/A
- Revenue Next Year
- BOOT $14.83
- BHVN $65.26
- P/E Ratio
- BOOT $18.59
- BHVN N/A
- Revenue Growth
- BOOT 8.31
- BHVN N/A
- 52 Week Low
- BOOT $95.28
- BHVN $26.57
- 52 Week High
- BOOT $176.64
- BHVN $55.72
- Technical
- Relative Strength Index (RSI)
- BOOT 37.72
- BHVN 35.77
- Support Level
- BOOT $103.47
- BHVN $28.22
- Resistance Level
- BOOT $109.30
- BHVN $31.18
- Average True Range (ATR)
- BOOT 4.19
- BHVN 1.56
- MACD
- BOOT 1.59
- BHVN 0.20
- Stochastic Oscillator
- BOOT 35.18
- BHVN 23.43
About BOOT Boot Barn Holdings Inc.
Boot Barn Holdings Inc operates specialty retail stores. The company sells western and work-related footwear, apparel, and accessories in the United States. It is a single operating segment, which includes net sales generated from its retail stores and e-commerce websites.
About BHVN Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.